Back to results
US 11,685,898 B2Granted
Cartilage-derived mesenchymal cell lines
AssigneeRhode Island Hospital
InventorsQian Chen, Chathuraka T. Jayasuriya
Life of this patent
Estimating the term…
Abstract
This invention is directed to, inter alia, stable cartilage-derived progenitor cell lines as well as methods for producing stable cartilage-derived progenitor cell lines from diseased human cartilaginous tissues and lesions. Also provided herein are methods for using cartilage-derived progenitor cell lines for treatment of cartilage and bone degenerative diseases.
Claims2
A stable human chondroprogenitor cell line or stable human osteochondroprogenitor cell line that expresses at least five times less lubricin (PRG4) relative to chondrocytes derived from healthy adult tissue, wherein:
- (a) the cell line expresses at least three times less matrilin 3 (MATN3) relative to chondrocytes derived from healthy adult tissue,
- (b) the cell line expresses two times less type I collagen (COL1) relative to bone marrow-derived mesenchymal stem cells (BM-MSCs);
- (c) the cell line expresses the mesenchymal cell surface markers CD29, CD49c, CD105, and CD166;
- (d) the cell line does not express the bone marrow-derived mesenchymal stem cell surface marker SSEA4;
- and
- (e) the cell line expresses the chondrocyte cell surface marker CD54.
3 more elements
Dependencies are inferred from the claim text.